Tumour growth and resistance to gemcitabine of pancreatic cancer cells are decreased by AP-2α overexpression

British Journal of Cancer

Volumn 101, Issue 4, 2009, Pages 637-644

  Jonckheere, N ^a,b   Fauquette, V ^a   Stechly, L ^a,c   Saint Laurent, N ^d   Aubert, S ^a,b,c   Susini, C ^d   Huet, G ^a,b,c   Porchet, N ^a,b,c   Van Seuningen, I ^a,b   Pigny, P ^a,b,c  

^a JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^b UNIV LILLE   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d INSERM   (France)

Author keywords

AP 2 ; Cell cycle; Gemcitabine; Mucin; Pancreatic cancer

Indexed keywords

CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 1C; CYCLIN G1; GEMCITABINE; TRANSCRIPTION FACTOR AP 2; TRANSCRIPTION FACTOR AP 2ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSACTIVATION;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; HUMANS; MICE; MICE, NUDE; MICROSCOPY, CONFOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PANCREATIC NEOPLASMS; TRANSCRIPTION FACTOR AP-2; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 68749086083     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605190     Document Type: Article

References (26)

1. Bosher JM, Totty NF, Hsuan JH, Williams T, Hurst HC (1996) A family of AP-2 proteins regulates c-erbB-2 expression in mammary carcinoma. Oncogene 13: 1701-1707
2. Chaturvedi P, Singh AP, Chakraborty S, Chauhan SC, Bafna S, Meza JL, Singh PK, Hollingsworth MA, Mehta PP, Batra SK (2008) MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells. Cancer Res 68: 2065-2070
3. Chaturvedi P, Singh AP, Moniaux N, Senapati S, Chakraborty S, Meza JL, Batra SK (2007) MUC4 mucin potentiates tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins. Mol Cancer Res 5: 309-320
4. Chua YJ, Cunningham D (2006) Chemotherapy for advanced pancreatic cancer. Best Pract Res Clin Gastroenterol 20: 327-348
5. Eckert D, Buhl S, Weber S, Jäger R, Schorle H (2005) The AP-2 family of transcription factors. Genome Biol 6: 246
6. Fauquette V, Aubert S, Groux-Degrotte S, Hemon B, Porchet N, Van Seuningen I, Pigny P (2007) Transcription factor AP-2α represses both the mucin MUC4 expression and pancreatic cancer cell proliferation. Carcinogenesis 28: 2305-2312
7. Fauquette V, Perrais M, Cerulis S, Jonckheere N, Ducourouble MP, Aubert JP, Pigny P, Van Seuningen I (2005) The antagonist regulation of the human MUC4 and ErbB-2 genes by the Ets protein PEA3 in pancreatic cancer cells: implications for the proliferation/differentiation balance in the cells. Biochem J 386: 35-45
8. Fischer C, Sanchez-Ruderisch H, Welzel M, Wiedenmann B, Sakai T, André S, Gabius H-J, Khachigian L, Detjen KM, Rosewicz S (2005) Galectin-1 interacts with the α5β1 fibronectin receptor to restrict carcinoma cell growth via induction of p21 and p27. J Biol Chem 280: 37266-37277
9. Giovannetti E, Mey V, Danesi R, Mosca I, Del Tacca M (2004) Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Clin Cancer Res 10: 2936-2943
10. Jepson S, Komatsu M, Haq B, Arango ME, Huang D, Carothers Carraway CA, Carraway KL (2002) MUC4/sialomucin complex, the intramembrane ErbB2 ligand, induces specific phosphorylation of ErbB2 and enhances expression of p27kip1, but does not activate mitogen-activated kinase or protein kinase B/Akt pathways. Oncogene 21: 7524-7532
11. Kalra AV, Campbell RB (2007) Mucin impedes cytotoxic effect of 5-FU against growth of human pancreatic cancer cells: overcoming cellular barriers for therapeutic gain. Br J Cancer 97: 910-918
12. Malumbres M, Barbacid M (2009) Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9: 153-166
13. Orso F, Penna E, Cimino D, Astanina E, Maione F, Valdembri D, Giraudo E, Serini G, Sismondi P, De Bortoli M, Taverna D (2008) AP-2α and AP-2γ regulate tumor progression via specific programs. FASEB J 22: 2704-2714
14. Perrais M, Pigny P, Ducourouble MP, Petitprez D, Porchet N, Aubert JP, Van Seuningen I (2001) Characterisation of human mucin gene MUC4 promoter: importance of growth factors and proinflammatory cytokines for its regulation in pancreatic cancer cells. J Biol Chem 276: 30923-30933
15. Ren J, Agata N, Chen D, Li Y, Yu WH, Huang L, Raina D, Chen W, Kharbanda S, Kufe D (2004) Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell 5: 163-175
16. Ruiz M, Troncoso P, Bruns C, Bar-Eli M (2001) AP-2α transcription factor expression is associated with luminal differentiation and is lost in prostate cancer. Clin Cancer Res 7: 4086-4095
17. Schneider G, Siveke JT, Eckel F, Schmid RM (2005) Pancreatic cancer: basic and clinical aspects. Gastroenterology 128: 1606-1625
18. Schwartz B, Melnikova VO, Tellez C, Mourad-Zeidan A, Blehm K, Zhao YJ, McCarty M, Adam L, Bar-Eli M (2007) Loss of AP-2α results in deregulation of E-cadherin and MMP-9 and an increase of tumorigeni-city of colon cancer cells in vivo. Oncogene 14: 4049-4058
19. Siragusa M, Zerilli M, Iovino F, Giovanna Francipane M, Lombardo Y, Ricci-Vitiani L, Di Gesu G, Todaro M, De Maria R, Stassi G (2007) MUC1 oncoprotein promotes refractoriness to chemotherapy in thyroid cancer cells. Cancer Res 67: 5522-5530
20. Sotillo R, Dubus P, Martin J, de la Cueva E, Ortega S, Malumbres M, Barbacid M (2001) Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors. EMBO J 20: 6637-6647
21. Swartz MJ, Batra SK, Varshney GC, Hollingsworth MA, Yeo CJ, Cameron JL, Wilentz RE, Hruban RH, Argani P (2002) MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. Am J Clin Pathol 117: 791-796
22. Tellez C, McCarty M, Ruiz M, Bar-Eli M (2003) Loss of AP-2α results in overexpression of protease-activated receptor-1 and correlates with the malignant phenotype of human melanoma. J Biol Chem 278: 46632-46642
23. Vernimmen D, Gueders M, Pisvin S, Delvenne P, Winkler R (2003) Different mechanisms are implicated in ERBB2 gene overexpression in breast and other cancers. Br J Cancer 89: 899-906
24. Wajapeyee N, Britto R, Ravishankar HM, Somasundaram K (2006) Apoptosis induction by AP-2α involves transcriptional repression of Bcl-2. J Biol Chem 281: 16207-16219
25. Wajapeyee N, Ganpat Raut C, Somasundaram K (2005) AP-2α status determines the chemosensitivity of cancer cells: implications in cancer chemotherapy. Cancer Res 65: 8628-8634
26. Wei D, Kanai M, Jia Z, Le X, Xie K (2008) Kruppel-like factor 4 induces p27kip1 expression in and suppresses the growth and metastasis of human pancreatic cancer cells. Cancer Res 68: 4631-4639